Bevacizumab in combination with chemotherapy in platinum-sensitive ovarian cancer

Chiara Della Pepa, Susana Banerjee

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Targeting angiogenesis is proving to be a successful approach in the management of ovarian cancer. The vascular endothelial growth factor inhibitor, bevacizumab, is the first angiogenesis inhibitor to have shown a significant progression-free survival advantage in the Phase III setting. There is now evidence supporting the use of bevacizumab in combination with chemotherapy for first-line and relapsed (platinum-sensitive and resistant) ovarian cancer. In this review, we summarize the positive Phase III trial (OCEANS [Ovarian Cancer Study Comparing Efficacy and Safety of Chemotherapy and Anti-Angiogenic Therapy in Platinum Sensitive Recurrent Disease]) that led to European Medicines Agency approval of bevacizumab in platinum-sensitive first relapse and discuss the best use of the drug in this disease.

Original languageEnglish
Pages (from-to)1025-1031
Number of pages7
JournalOncoTargets and Therapy
Volume7
DOIs
Publication statusPublished - Jun 19 2014

Fingerprint

Combination Drug Therapy
Platinum
Ovarian Neoplasms
Angiogenesis Inhibitors
Vascular Endothelial Growth Factor A
Disease-Free Survival
Safety
Recurrence
Drug Therapy
Pharmaceutical Preparations
Bevacizumab
Therapeutics

Keywords

  • Antiangiogenic
  • Ovarian
  • Recurrent

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Cite this

Bevacizumab in combination with chemotherapy in platinum-sensitive ovarian cancer. / Della Pepa, Chiara; Banerjee, Susana.

In: OncoTargets and Therapy, Vol. 7, 19.06.2014, p. 1025-1031.

Research output: Contribution to journalArticle

Della Pepa, Chiara ; Banerjee, Susana. / Bevacizumab in combination with chemotherapy in platinum-sensitive ovarian cancer. In: OncoTargets and Therapy. 2014 ; Vol. 7. pp. 1025-1031.
@article{57e81a7e948c4ce29c6198e8864610f5,
title = "Bevacizumab in combination with chemotherapy in platinum-sensitive ovarian cancer",
abstract = "Targeting angiogenesis is proving to be a successful approach in the management of ovarian cancer. The vascular endothelial growth factor inhibitor, bevacizumab, is the first angiogenesis inhibitor to have shown a significant progression-free survival advantage in the Phase III setting. There is now evidence supporting the use of bevacizumab in combination with chemotherapy for first-line and relapsed (platinum-sensitive and resistant) ovarian cancer. In this review, we summarize the positive Phase III trial (OCEANS [Ovarian Cancer Study Comparing Efficacy and Safety of Chemotherapy and Anti-Angiogenic Therapy in Platinum Sensitive Recurrent Disease]) that led to European Medicines Agency approval of bevacizumab in platinum-sensitive first relapse and discuss the best use of the drug in this disease.",
keywords = "Antiangiogenic, Ovarian, Recurrent",
author = "{Della Pepa}, Chiara and Susana Banerjee",
year = "2014",
month = "6",
day = "19",
doi = "10.2147/OTT.S40527",
language = "English",
volume = "7",
pages = "1025--1031",
journal = "OncoTargets and Therapy",
issn = "1178-6930",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Bevacizumab in combination with chemotherapy in platinum-sensitive ovarian cancer

AU - Della Pepa, Chiara

AU - Banerjee, Susana

PY - 2014/6/19

Y1 - 2014/6/19

N2 - Targeting angiogenesis is proving to be a successful approach in the management of ovarian cancer. The vascular endothelial growth factor inhibitor, bevacizumab, is the first angiogenesis inhibitor to have shown a significant progression-free survival advantage in the Phase III setting. There is now evidence supporting the use of bevacizumab in combination with chemotherapy for first-line and relapsed (platinum-sensitive and resistant) ovarian cancer. In this review, we summarize the positive Phase III trial (OCEANS [Ovarian Cancer Study Comparing Efficacy and Safety of Chemotherapy and Anti-Angiogenic Therapy in Platinum Sensitive Recurrent Disease]) that led to European Medicines Agency approval of bevacizumab in platinum-sensitive first relapse and discuss the best use of the drug in this disease.

AB - Targeting angiogenesis is proving to be a successful approach in the management of ovarian cancer. The vascular endothelial growth factor inhibitor, bevacizumab, is the first angiogenesis inhibitor to have shown a significant progression-free survival advantage in the Phase III setting. There is now evidence supporting the use of bevacizumab in combination with chemotherapy for first-line and relapsed (platinum-sensitive and resistant) ovarian cancer. In this review, we summarize the positive Phase III trial (OCEANS [Ovarian Cancer Study Comparing Efficacy and Safety of Chemotherapy and Anti-Angiogenic Therapy in Platinum Sensitive Recurrent Disease]) that led to European Medicines Agency approval of bevacizumab in platinum-sensitive first relapse and discuss the best use of the drug in this disease.

KW - Antiangiogenic

KW - Ovarian

KW - Recurrent

UR - http://www.scopus.com/inward/record.url?scp=84902988353&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902988353&partnerID=8YFLogxK

U2 - 10.2147/OTT.S40527

DO - 10.2147/OTT.S40527

M3 - Article

AN - SCOPUS:84902988353

VL - 7

SP - 1025

EP - 1031

JO - OncoTargets and Therapy

JF - OncoTargets and Therapy

SN - 1178-6930

ER -